Clinical Trials Directory

Trials / Completed

CompletedNCT01731912

Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer

Degarelix Acetate Prior to Radiation Therapy

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
16 (actual)
Sponsor
University of Washington · Academic / Other
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

This pilot clinical trial studies how well degarelix acetate before and during radiation therapy works in treating patients with prostate cancer. Androgens can cause the growth of prostate cancer cells. Drugs, such as degarelix acetate, may lessen the amount of androgens made by the body. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving degarelix acetate together with radiation therapy may work better in treating prostate cancer.

Detailed description

PRIMARY OBJECTIVES: I. To evaluate the effect of neoadjuvant degarelix (degarelix acetate) on prostate dihydrotestosterone (DHT) and testosterone levels. SECONDARY OBJECTIVES: I. To determine the effect of degarelix acetate on androgen-regulated gene expression and apoptosis as assessed by immunohistochemistry, complementary deoxyribonucleic acid (cDNA) microarray analysis and reverse transcriptase (RT)-polymerase chain reaction (PCR). II. To determine the effect of degarelix acetate on follicle stimulating hormone (FSH) and FSH receptor expression in prostate cancer and surrounding microenvironment. OUTLINE: Patients receive degarelix acetate subcutaneously (SC) on day 1. Treatment repeats every 4 weeks for up to 6 courses. Beginning at week 15, patients also undergo standard external beam radiation therapy (EBRT) for 8.5 weeks.

Conditions

Interventions

TypeNameDescription
DRUGDegarelixGiven SC
RADIATIONExternal Beam Radiation TherapyUndergo standard EBRT
OTHERLaboratory Biomarker AnalysisCorrelative studies

Timeline

Start date
2013-05-01
Primary completion
2016-09-01
Completion
2016-09-01
First posted
2012-11-22
Last updated
2019-01-18
Results posted
2019-01-18

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01731912. Inclusion in this directory is not an endorsement.